PROVECTUS BIOPHARMACEUTICALS, INC.

Form 8-K March 21, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 21, 2014

PROVECTUS BIOPHARMACEUTICALS, INC.

(Exact name of registrant as specified in charter)

Delaware 0-9410 90-0031917 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.)

7327 Oak Ridge Hwy., Knoxville, Tennessee 37931 (Address of Principal Executive Offices)

(866) 594-5999 (Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01.

Regulation FD Disclosure.

On March 21, 2014, Provectus Biopharmaceuticals, Inc. submitted via overnight courier for Monday, March, 24, 2014 delivery an application to the Food and Drug Administration for Breakthrough Therapy Designation ("BTD") for its oncology drug PV-10 for the treatment of melanoma.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 21, 2014

PROVECTUS BIOPHARMACEUTICALS, INC.

By: /s/ Peter R.
Culpepper
Peter R.
Culpepper
Chief Financial
Officer and Chief
Operating Officer